ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Most recent advances in pharmacotherapy for female sexual dysfunctions
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 226332" data-attributes="member: 13851"><p><strong>Article highlights</strong></p><p></p><p><em><strong>● The biopsychosocial model is essential to diagnose and treat FSDs, as well as to guide the development of new pharmacotherapies and multimodal approaches </strong></em></p><p></p><p><strong><em>● The DSM-V disorder named female sexual interest/arousal disorder (FSIAD) merged hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) into a new entity not well captured by the validated psychometric tools available for diagnosis </em></strong></p><p><strong><em></em></strong></p><p><strong><em>● Premenopausal and postmenopausal women should follow a standard process of care (POC) to establish an adequate therapeutic plan </em></strong></p><p><strong><em></em></strong></p><p><strong><em>● Hypoactive sexual desire disorder (HSDD) and associated sexual symptoms may be treated with two approved psychoactive agents (flibanserin on a daily basis and bremelanotide on-demand) in premenopausal women and with daily transdermal testosterone (approved for use in males) at the physiological dose in postmenopausal women </em></strong></p><p><strong><em></em></strong></p><p><strong><em>● Other psychoactive agents (bupropion, buspirone, and trazodone) are used off-label in the management of FSDs, especially when associated with antidepressant agents </em></strong></p><p><strong><em></em></strong></p><p><strong><em>● Evidence-based treatments [local estrogen therapy (LET), intravaginal dehydroepiandrosterone (DHEA), oral Ospemifene] are available to manage vulvovaginal atrophy/genitourinary syndrome of menopause (VVA/GSM) to avoid the negative vicious circle that may lead to HSDD in postmenopausal women </em></strong></p><p><strong><em></em></strong></p><p><strong><em>● Only a few of the most recent candidate drugs to treat FSDs are in late development due to low levels of evidence </em></strong></p><p><strong><em></em></strong></p><p><strong><em>● Two on-demand oral combined drugs [Lybrido: sildenafil (50 mg) plus testosterone (0.5 mg) and Lybridos: testosterone (0.5 mg) with buspirone (10 mg)] aim to treat FSIAD, due to lack of sensitivity to excitation and dysfunctional sexual inhibition, respectively. The novel combination of bupropion and trazodone at different dosages (Lorexys) offers another</em></strong><em><strong> potential multifunctional solution</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 226332, member: 13851"] [B]Article highlights[/B] [I][B]● The biopsychosocial model is essential to diagnose and treat FSDs, as well as to guide the development of new pharmacotherapies and multimodal approaches [/B][/I] [B][I]● The DSM-V disorder named female sexual interest/arousal disorder (FSIAD) merged hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) into a new entity not well captured by the validated psychometric tools available for diagnosis ● Premenopausal and postmenopausal women should follow a standard process of care (POC) to establish an adequate therapeutic plan ● Hypoactive sexual desire disorder (HSDD) and associated sexual symptoms may be treated with two approved psychoactive agents (flibanserin on a daily basis and bremelanotide on-demand) in premenopausal women and with daily transdermal testosterone (approved for use in males) at the physiological dose in postmenopausal women ● Other psychoactive agents (bupropion, buspirone, and trazodone) are used off-label in the management of FSDs, especially when associated with antidepressant agents ● Evidence-based treatments [local estrogen therapy (LET), intravaginal dehydroepiandrosterone (DHEA), oral Ospemifene] are available to manage vulvovaginal atrophy/genitourinary syndrome of menopause (VVA/GSM) to avoid the negative vicious circle that may lead to HSDD in postmenopausal women ● Only a few of the most recent candidate drugs to treat FSDs are in late development due to low levels of evidence ● Two on-demand oral combined drugs [Lybrido: sildenafil (50 mg) plus testosterone (0.5 mg) and Lybridos: testosterone (0.5 mg) with buspirone (10 mg)] aim to treat FSIAD, due to lack of sensitivity to excitation and dysfunctional sexual inhibition, respectively. The novel combination of bupropion and trazodone at different dosages (Lorexys) offers another[/I][/B][I][B] potential multifunctional solution[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Most recent advances in pharmacotherapy for female sexual dysfunctions
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top